A new perspective in sepsis treatment: could RGD-dependent integrins be novel targets?
journal contributionposted on 03.03.2021, 11:47 authored by Danielle NaderDanielle Nader, Gerard CurleyGerard Curley, Steven KerriganSteven Kerrigan
Sepsis is a life-threatening condition caused by the response of the body to an infection, and has recently been regarded as a global health priority because of the lack of effective treatments available. Vascular endothelial cells have a crucial role in sepsis and are believed to be a major target of pathogens during the early stages of infection. Accumulating evidence suggests that common sepsis pathogens, including bacteria, fungi, and viruses, all contain a critical integrin recognition motif, Arg-Gly-Asp (RGD), in their major cell wall-exposed proteins that might act as ligands to crosslink to vascular endothelial cells, triggering systemic dysregulation resulting in sepsis. In this review, we discuss the potential of anti-integrin therapy in the treatment of sepsis and septic shock.
Science Foundation Ireland (SFI) under Grant Number 13/CDA/2119
Enterprise Ireland (EI) under Grant Number CF-2017-0684-P
CommentsThe original article is available at https://www.sciencedirect.com/
Published CitationNader D, Curley GF, Kerrigan SW. A new perspective in sepsis treatment: could RGD-dependent integrins be novel targets? Drug Discovery Today. 2020(12):2317-2325.
Publication Date6 October 2020
- Anaesthetics and Critical Care
- Beaumont Hospital
- School of Pharmacy and Biomolecular Sciences
- Irish Centre for Vascular Biology
- Vascular Biology
- Biomaterials and Regenerative Medicine
- Immunity, Infection and Inflammation
- Accepted Version (Postprint)